Celgene's New Regime: Hugin And Alles Discuss Handing Over The Reins
This article was originally published in Scrip
Mark Alles has been in his first pharma chief executive role for six weeks, after stepping into former Celgene Corp. leader Bob Hugin's shoes in March. While Alles has been with the company for 12 years and in the pharma industry for three decades he brings new skills to the top spot at Celgene and a keen eye for keeping science at the fore of his corporate decision making.
You may also be interested in...
Median tenure of large cap US biotech CEOs has decreased from 11 years in 2007 to one year in 2017, Leerink analyst Geoffrey Porges determined in an analysis of seven biotechs over 15 years.
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.